WO2008143240A1 - 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法 - Google Patents
特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法 Download PDFInfo
- Publication number
- WO2008143240A1 WO2008143240A1 PCT/JP2008/059196 JP2008059196W WO2008143240A1 WO 2008143240 A1 WO2008143240 A1 WO 2008143240A1 JP 2008059196 W JP2008059196 W JP 2008059196W WO 2008143240 A1 WO2008143240 A1 WO 2008143240A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oral preparation
- organic acid
- elution property
- chemical stability
- improvement
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Abstract
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2687558A CA2687558C (en) | 2007-05-21 | 2008-05-20 | Oral preparation comprising specific organic acid, and method for improvement in elution property and chemical stability of oral preparation |
KR1020097024058A KR101520311B1 (ko) | 2007-05-21 | 2008-05-20 | 특정 유기산을 함유하는 경구 제제, 및 경구 제제의 용출성과 화학적 안정성의 개선 방법 |
US12/600,021 US9084817B2 (en) | 2007-05-21 | 2008-05-20 | Oral preparation comprising specific organic acid, and method for improvement in elution property and chemical stability of oral preparation |
EP08752992.1A EP2168579B1 (en) | 2007-05-21 | 2008-05-20 | Oral preparation comprising specific organic acid, and method for improvement in dissolution property and chemical stability of oral preparation |
AU2008254038A AU2008254038B2 (en) | 2007-05-21 | 2008-05-20 | Oral preparation comprising specific organic acid, and method for improvement in elution property and chemical stability of oral preparation |
CN2008800256025A CN101848713B (zh) | 2007-05-21 | 2008-05-20 | 含有特定的有机酸的口服制剂以及口服制剂的溶出性和化学稳定性的改善方法 |
ES08752992.1T ES2648037T3 (es) | 2007-05-21 | 2008-05-20 | Preparación oral que comprende un ácido orgánico específico y método para mejorar la propiedad de disolución y la estabilidad química de la preparación oral |
JP2009515239A JP5343845B2 (ja) | 2007-05-21 | 2008-05-20 | 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007-133854 | 2007-05-21 | ||
JP2007133854 | 2007-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008143240A1 true WO2008143240A1 (ja) | 2008-11-27 |
Family
ID=40031937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/059196 WO2008143240A1 (ja) | 2007-05-21 | 2008-05-20 | 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9084817B2 (ja) |
EP (1) | EP2168579B1 (ja) |
JP (1) | JP5343845B2 (ja) |
KR (1) | KR101520311B1 (ja) |
CN (1) | CN101848713B (ja) |
AU (1) | AU2008254038B2 (ja) |
CA (1) | CA2687558C (ja) |
ES (1) | ES2648037T3 (ja) |
WO (1) | WO2008143240A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013172297A1 (ja) * | 2012-05-14 | 2013-11-21 | 塩野義製薬株式会社 | 6,7-不飽和-7-カルバモイルモルヒナン誘導体含有製剤 |
WO2014046129A1 (ja) | 2012-09-19 | 2014-03-27 | 大鵬薬品工業株式会社 | 溶出性及び/又は吸収性が改善された経口投与用医薬組成物 |
JP2016153433A (ja) * | 2011-08-10 | 2016-08-25 | 第一三共株式会社 | ジアミン誘導体含有医薬組成物 |
JP2020521795A (ja) * | 2017-05-31 | 2020-07-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | (E)−4−(2−(アミノメチル)−3−フルオロアリルオキシ)−N−tert−ブチルベンズアミドを含む医薬組成物および医薬剤形、それらの調製方法、治療方法およびそれらの使用 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2715028T3 (es) * | 2012-06-05 | 2019-05-31 | Neuroderm Ltd | Composiciones que comprenden apomorfina y ácidos orgánicos y sus usos |
EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
HUE045725T2 (hu) | 2014-02-13 | 2020-01-28 | Incyte Corp | Ciklopropilaminok mint LSD1 inhibitorok |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
AU2015217073B2 (en) | 2014-02-13 | 2019-08-22 | Incyte Holdings Corporation | Cyclopropylamines as LSD1 inhibitors |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪 |
WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
TWI714567B (zh) | 2015-04-03 | 2021-01-01 | 美商英塞特公司 | 作為lsd1抑制劑之雜環化合物 |
MY189367A (en) | 2015-08-12 | 2022-02-08 | Incyte Corp | Salts of an lsd1 inhibitor |
EP3445339B1 (en) * | 2016-04-22 | 2023-08-23 | Incyte Corporation | Formulations of an lsd1 inhibitor |
US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999002158A1 (fr) * | 1997-07-11 | 1999-01-21 | Toray Industries, Inc. | Compositions medicinales stables, contenant des derives de 4,5-epoxymorphinane |
WO2005094826A1 (ja) * | 2004-03-30 | 2005-10-13 | Toray Industries, Inc. | 止痒剤 |
JP2006509772A (ja) * | 2002-11-25 | 2006-03-23 | デュレクト コーポレーション | オピオイドおよびオピオイド誘導体の高濃度製剤 |
WO2006049248A1 (ja) * | 2004-11-04 | 2006-05-11 | Toray Industries, Inc. | 鎮痛剤 |
WO2007055184A1 (ja) * | 2005-11-09 | 2007-05-18 | Toray Industries, Inc. | 機能性腸障害の治療または予防剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020198246A1 (en) * | 1998-09-30 | 2002-12-26 | Ono Pharmaceutical Co., Ltd. | Agent for preventing and/or treating sinusitis |
US20040137052A1 (en) * | 2001-12-25 | 2004-07-15 | Yoshihiro Uchiyama | Acid-containing preparations |
WO2003077867A2 (en) * | 2002-03-14 | 2003-09-25 | Euro-Celtique, S.A. | Naltrexone hydrochloride compositions |
KR20070057218A (ko) * | 2004-08-30 | 2007-06-04 | 가부시키가이샤 가네카 | 미토콘드리아 활성화제 |
-
2008
- 2008-05-20 ES ES08752992.1T patent/ES2648037T3/es active Active
- 2008-05-20 JP JP2009515239A patent/JP5343845B2/ja not_active Expired - Fee Related
- 2008-05-20 US US12/600,021 patent/US9084817B2/en not_active Expired - Fee Related
- 2008-05-20 KR KR1020097024058A patent/KR101520311B1/ko not_active IP Right Cessation
- 2008-05-20 AU AU2008254038A patent/AU2008254038B2/en not_active Ceased
- 2008-05-20 EP EP08752992.1A patent/EP2168579B1/en not_active Not-in-force
- 2008-05-20 CN CN2008800256025A patent/CN101848713B/zh not_active Expired - Fee Related
- 2008-05-20 CA CA2687558A patent/CA2687558C/en not_active Expired - Fee Related
- 2008-05-20 WO PCT/JP2008/059196 patent/WO2008143240A1/ja active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999002158A1 (fr) * | 1997-07-11 | 1999-01-21 | Toray Industries, Inc. | Compositions medicinales stables, contenant des derives de 4,5-epoxymorphinane |
JP2006509772A (ja) * | 2002-11-25 | 2006-03-23 | デュレクト コーポレーション | オピオイドおよびオピオイド誘導体の高濃度製剤 |
WO2005094826A1 (ja) * | 2004-03-30 | 2005-10-13 | Toray Industries, Inc. | 止痒剤 |
WO2006049248A1 (ja) * | 2004-11-04 | 2006-05-11 | Toray Industries, Inc. | 鎮痛剤 |
WO2007055184A1 (ja) * | 2005-11-09 | 2007-05-18 | Toray Industries, Inc. | 機能性腸障害の治療または予防剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2168579A4 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016153433A (ja) * | 2011-08-10 | 2016-08-25 | 第一三共株式会社 | ジアミン誘導体含有医薬組成物 |
WO2013172297A1 (ja) * | 2012-05-14 | 2013-11-21 | 塩野義製薬株式会社 | 6,7-不飽和-7-カルバモイルモルヒナン誘導体含有製剤 |
JP5818219B2 (ja) * | 2012-05-14 | 2015-11-18 | 塩野義製薬株式会社 | 6,7−不飽和−7−カルバモイルモルヒナン誘導体含有製剤 |
WO2014046129A1 (ja) | 2012-09-19 | 2014-03-27 | 大鵬薬品工業株式会社 | 溶出性及び/又は吸収性が改善された経口投与用医薬組成物 |
JP5791817B2 (ja) * | 2012-09-19 | 2015-10-07 | 大鵬薬品工業株式会社 | 溶出性及び/又は吸収性が改善された経口投与用医薬組成物 |
JP2020521795A (ja) * | 2017-05-31 | 2020-07-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | (E)−4−(2−(アミノメチル)−3−フルオロアリルオキシ)−N−tert−ブチルベンズアミドを含む医薬組成物および医薬剤形、それらの調製方法、治療方法およびそれらの使用 |
Also Published As
Publication number | Publication date |
---|---|
AU2008254038B2 (en) | 2013-01-10 |
ES2648037T3 (es) | 2017-12-28 |
US9084817B2 (en) | 2015-07-21 |
AU2008254038A1 (en) | 2008-11-27 |
KR101520311B1 (ko) | 2015-05-14 |
CN101848713B (zh) | 2012-04-11 |
EP2168579A1 (en) | 2010-03-31 |
EP2168579A4 (en) | 2012-12-12 |
KR20100017119A (ko) | 2010-02-16 |
JP5343845B2 (ja) | 2013-11-13 |
CN101848713A (zh) | 2010-09-29 |
US20100215750A1 (en) | 2010-08-26 |
CA2687558A1 (en) | 2008-11-27 |
EP2168579B1 (en) | 2017-10-11 |
CA2687558C (en) | 2015-07-14 |
JPWO2008143240A1 (ja) | 2010-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008143240A1 (ja) | 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法 | |
WO2007138472A3 (en) | Triazolopyridazine derivatives | |
WO2008057802A3 (en) | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same | |
TW200716202A (en) | Pediatric formulation of topiramate | |
WO2007061360A3 (en) | Novel 3-bicyclocarbonylaminopyridine-2-carboxamides or 3-bicyclocarbonylaminopyrazine-2-carboxamides | |
WO2007122580A3 (en) | Compositions of phenylephrine useful for treatment of respiratory illness | |
WO2007135527A3 (en) | Benzimidazolyl compounds | |
WO2009016410A3 (en) | Chemical compounds 831 | |
WO2008132600A3 (en) | Trpv1 antagonists and uses thereof | |
WO2006116733A3 (en) | Protein kinase inhibitors | |
WO2008022286A3 (en) | Small molecule inhibitors of kynurenine-3-monooxygenase | |
WO2006085335A3 (en) | Pharmaceutical composition of acid labile substances | |
WO2008001195A3 (en) | Novel processes for the preparation of dpp iv inhibitors | |
WO2006077024A3 (en) | 5-aminoindole derivatives | |
WO2009007137A3 (en) | Pharmaceutical composition for topical application of poorly soluble compounds | |
WO2008026048A3 (en) | Stable injectable pharmaceutical compositions of docetaxel | |
MX2007005336A (es) | Analgesicos. | |
WO2007097888A3 (en) | Fluoroquinolone carboxylic acid salt compositions | |
EP1968606A4 (en) | PREPARATION OF PHARMACEUTICAL SALTS OF 3-O- (3 ', 3'-DIMETHYLSUCCINYL) BETULINIC ACID | |
EP1974731A4 (en) | ANTITUSSIVE AGENT | |
WO2008043366A3 (en) | Three-domain compounds for transmembrane delivery | |
EP1935417A4 (en) | COMPOSITION FOR USE IN PREVENTING A HYPOGLYCEMIC STATE | |
WO2010013835A3 (en) | Solid pharmaceutical composition | |
HK1167388A1 (en) | Anticancer compound and pharmaceutical composition containing the same | |
WO2008093838A1 (ja) | スルファモイル基を有するピリジルイミダゾリジン誘導体、およびその医薬としての使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880025602.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08752992 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009515239 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2687558 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20097024058 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008254038 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2008752992 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008752992 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12600021 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2008254038 Country of ref document: AU Date of ref document: 20080520 Kind code of ref document: A |